Abstract

The IORA CCOP will expand its long term objectives of quality clinical cancer treatment research by utilizing treatment protocols and methodologies for cancer patients in Central IL and beyond. This participation fosters the growth of a scientifically viable community cancer network by utilizing the NCCTG, ECOG and RTOG as Data Bases. The expansion includes emphasis on current cancer control through early detection, prevention, screening, pretreatment evaluation, treatment, continuing care and rehabilitation. Expanded involvement of the primary care physician early in treatment will be emphasized. Continued involvement of minority and underserved population is planned. The most current treatment protocols of NCCTG, ECOG and RTOG will be employed. Interdisciplinary cooperation of the Oncology Care Team's medical, diagnostic and support personnel coordinates its efforts in all phases of patient caring. The team's primary goal is improving the patient's quality of life, care and survival. A region of 16 counties and 18 affiliate hospitals, the population served is over 960,000. Patients of small community hospitals will receive the newest approach and/or innovative treatment and medications without having to travel great distances to a metropolitan medical center. As consultants, the CCOP oncology physicians have established an effective referral base, providing educational resources for the community physicians to enhance prevention and educational initiatives of CCOP. Examples of current educational cancer control projects include breast cancer examination and prevention, smokeless tobacco/stop smoking, testicular exam, diet and nutrition, stool Hemoccult and HemoQuant tests. All programs will be structured to the general public and primary care physicians and include cancer publications, televised programs, public service announcements and support groups. Modern medical imaging devices such as SPECT, MRI, CAT scan, ultrasound and angiography will be used to assist in early cancer detection. These goals will be achieved with ongoing utilization of physician leadership of IORA, CCOP and the staff of affiliate hospitals/clinics using research bases. Methodologies include a protocol review system at two component hospitals, the certified American College of Surgeons computerized cancer registry, cancer coordinating committee, IORA Data Management coordination, a centralized patient log system and Quality Control systems. IORA and its Oncology Care Team places a high priority on CCOP with continued commitment to its growth and services to patients.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035113-05
Application #
3557508
Study Section
(SRC)
Project Start
1983-09-01
Project End
1990-05-31
Budget Start
1988-06-01
Budget End
1989-05-31
Support Year
5
Fiscal Year
1988
Total Cost
Indirect Cost

  Institution

Name
Methodist Medical Center of Illinois
Department
Type
DUNS #
City
Peoria
State
IL
Country
United States
Zip Code
61636

  Publications

Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Apoe, Ogheneruona; Jung, Sin-Ho; Liu, Heshan et al. (2016) Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data. Am J Hematol Oncol 12:4-9
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Zhao, Yujie; Foster, Nathan R; Meyers, Jeffrey P et al. (2015) A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. J Thorac Oncol 10:172-80
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Rule, William G; Foster, Nathan R; Meyers, Jeffrey P et al. (2015) Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis. J Geriatr Oncol 6:119-26

Showing the most recent 10 out of 165 publications